HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yukinari Kato Selected Research

podocalyxin

10/2021Epitope Mapping of a Cancer-Specific Anti-Podocalyxin Monoclonal Antibody (PcMab-60) Using Enzyme-Linked Immunosorbent Assay and Surface Plasmon Resonance.
12/2020A cancer-specific anti-podocalyxin monoclonal antibody (60-mG2a-f) exerts antitumor effects in mouse xenograft models of pancreatic carcinoma.
9/2018Podocalyxin is crucial for the growth of oral squamous cell carcinoma cell line HSC-2.
6/201847-mG2a: A Mouse IgG2a-Type of PcMab-47 Useful for Detecting Podocalyxin in Esophageal Cancers by Immunohistochemistry.
4/2018Anti-podocalyxin antibody exerts antitumor effects via antibody-dependent cellular cytotoxicity in mouse xenograft models of oral squamous cell carcinoma.
4/2018Anti-Podocalyxin Monoclonal Antibody 47-mG2a Detects Lung Cancers by Immunohistochemistry.
10/2017Immunohistochemical Analysis Using Antipodocalyxin Monoclonal Antibody PcMab-47 Demonstrates Podocalyxin Expression in Oral Squamous Cell Carcinomas.
8/2017Antipodocalyxin Antibody chPcMab-47 Exerts Antitumor Activity in Mouse Xenograft Models of Colorectal Adenocarcinomas.
9/2008Podocalyxin expression in malignant astrocytic tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Yukinari Kato Research Topics

Disease

132Neoplasms (Cancer)
09/2022 - 12/2003
31Neoplasm Metastasis (Metastasis)
02/2022 - 09/2004
26Glioma (Gliomas)
09/2018 - 12/2009
22Glioblastoma (Glioblastoma Multiforme)
10/2021 - 05/2006
17Mouth Neoplasms (Oral Cancer)
10/2021 - 10/2017
12Squamous Cell Carcinoma (Epidermoid Carcinoma)
08/2022 - 04/2015
12Squamous Cell Carcinoma of Head and Neck
02/2022 - 10/2017
12Melanoma (Melanoma, Malignant)
01/2022 - 01/2016
9Lung Neoplasms (Lung Cancer)
01/2022 - 12/2017
9Breast Neoplasms (Breast Cancer)
08/2021 - 12/2012
9Brain Neoplasms (Brain Tumor)
10/2020 - 12/2012
8Stomach Neoplasms (Stomach Cancer)
08/2021 - 12/2017
7Colorectal Neoplasms (Colorectal Cancer)
06/2022 - 08/2017
7Osteosarcoma (Osteogenic Sarcoma)
02/2022 - 12/2013
7Colonic Neoplasms (Colon Cancer)
08/2021 - 10/2017
7Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
04/2015 - 01/2013
5Pancreatic Neoplasms (Pancreatic Cancer)
01/2022 - 12/2017
5Malignant Mesothelioma
07/2021 - 06/2013
5Mesothelioma
01/2021 - 12/2017
5Infections
01/2020 - 01/2017
5Oligodendroglioma
06/2019 - 12/2009
5Astrocytoma (Pilocytic Astrocytoma)
07/2012 - 05/2006
4Carcinogenesis
06/2022 - 01/2008
4B-Cell Lymphoma (Lymphoma, B Cell)
12/2021 - 08/2020
4Disease Progression
02/2021 - 01/2017
3Esophageal Neoplasms (Esophageal Cancer)
08/2022 - 12/2017
3Renal Cell Carcinoma (Grawitz Tumor)
04/2022 - 01/2016
3Persistent Infection
12/2021 - 01/2017
3Deltaretrovirus Infections (BLV Infection)
01/2021 - 01/2018
3Paratuberculosis (Johne's Disease)
01/2020 - 01/2018
2Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
04/2022 - 02/2022
2Necrosis
11/2021 - 04/2015
2Adenocarcinoma
08/2021 - 12/2020
2Leukemia
06/2021 - 03/2013
2Carcinoma (Carcinomatosis)
10/2020 - 06/2018
2Sarcoma (Soft Tissue Sarcoma)
08/2020 - 01/2017
2Bacterial Infections (Bacterial Infection)
01/2020 - 01/2019
2Intellectual Disability (Idiocy)
09/2018 - 10/2016
2Cholangiocarcinoma
10/2016 - 01/2015
2Giant Cell Tumors (Giant Cell Tumor)
04/2015 - 01/2015

Drug/Important Bio-Agent (IBA)

87Monoclonal AntibodiesIBA
08/2022 - 12/2003
30Immunoglobulin G (IgG)IBA
06/2022 - 01/2010
23Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA
06/2019 - 12/2009
21Proteins (Proteins, Gene)FDA Link
09/2022 - 11/2004
18AntibodiesIBA
04/2022 - 08/2008
17C-Type Lectins (C-Type Lectin)IBA
01/2022 - 08/2008
16Glycoproteins (Glycoprotein)IBA
08/2022 - 06/2013
15SialoglycoproteinsIBA
10/2021 - 12/2003
12Complement System Proteins (Complement)IBA
02/2022 - 11/2012
11LigandsIBA
06/2022 - 04/2012
11MucinsIBA
01/2022 - 06/2006
10ErbB Receptors (EGF Receptor)IBA
08/2022 - 12/2017
10human ERBB2 proteinIBA
12/2021 - 08/2017
9AntigensIBA
12/2021 - 12/2003
9podocalyxinIBA
10/2021 - 09/2008
9Trastuzumab (Herceptin)FDA Link
08/2021 - 08/2017
8Biomarkers (Surrogate Marker)IBA
09/2022 - 01/2018
6Pharmaceutical PreparationsIBA
10/2020 - 04/2007
5B7-H1 AntigenIBA
01/2022 - 01/2017
5Telomerase (Telomerase Reverse Transcriptase)IBA
01/2022 - 01/2018
5DNA (Deoxyribonucleic Acid)IBA
01/2020 - 04/2011
4Chimeric Antigen ReceptorsIBA
09/2022 - 03/2016
4Membrane Glycoproteins (Membrane Glycoprotein)IBA
06/2022 - 04/2018
4Protein Isoforms (Isoforms)IBA
05/2022 - 07/2018
4ImmunosorbentsIBA
10/2021 - 08/2017
4EnzymesIBA
10/2021 - 08/2017
4EpitopesIBA
10/2021 - 10/2016
4Dinoprostone (PGE2)FDA Link
12/2020 - 01/2018
4Arginine (L-Arginine)FDA Link
01/2015 - 03/2011
3Epithelial Cell Adhesion MoleculeIBA
06/2022 - 12/2020
3G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA
04/2022 - 04/2022
3Immune Checkpoint InhibitorsIBA
01/2022 - 01/2016
3Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA
01/2020 - 01/2018
3Biological ProductsIBA
01/2020 - 12/2009
3Peptides (Polypeptides)IBA
01/2019 - 07/2018
3Keratan SulfateIBA
08/2014 - 04/2008
2ParaffinIBA
06/2022 - 01/2022
2Formaldehyde (Formol)FDA Link
06/2022 - 01/2022
2Coloring Agents (Dyes)IBA
06/2022 - 12/2016
2Chemokine ReceptorsIBA
04/2022 - 04/2022
2CCR ReceptorsIBA
04/2022 - 04/2022
2Surface Antigens (Surface Antigen)IBA
02/2022 - 03/2016
2Rituximab (Mabthera)FDA Link
02/2022 - 10/2020
2Threonine (L-Threonine)FDA Link
01/2022 - 01/2020
2Indicators and Reagents (Reagents)IBA
01/2022 - 04/2015
2Immunoglobulin M (IgM)IBA
10/2021 - 12/2020
2Indocyanine Green (Cardio-Green)FDA LinkGeneric
01/2020 - 01/2018
2SialomucinsIBA
05/2019 - 06/2013
2Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
07/2018 - 12/2017
2Blocking AntibodiesIBA
01/2018 - 01/2017
22-toluenesulfonamide (OTS)IBA
02/2015 - 12/2003
2Codon (Codons)IBA
01/2013 - 03/2011
2Platelet Activating FactorIBA
01/2008 - 11/2006
2Messenger RNA (mRNA)IBA
05/2006 - 11/2004
1CytokinesIBA
09/2022
1Adapalene (Differin)FDA LinkGeneric
08/2022
1Nerve Growth Factor Receptor (Nerve Growth Factor Receptor, Low Affinity)IBA
08/2022

Therapy/Procedure

39Therapeutics
06/2022 - 11/2006
10Immunotherapy
06/2022 - 11/2012
2Radioimmunotherapy
01/2021 - 05/2019